✦ LIBER ✦

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Scribed by Brufsky, A.

Book ID: 122364468
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 99 KB
Volume: 22
Category: Article
ISSN: 1043-321X
DOI: 10.1016/j.breastdis.2011.10.016

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RIBBON-1: Randomized, Double-Blind, Plac

RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative, Locally Recurrent or Metastatic Breast Cancer

✍ Robert, N. J.; Dieras, V.; Glaspy, J.; Brufsky, A. M.; Bondarenko, I.; Lipatov, 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 317 KB

5016 Efficacy in patient subgroups in RI

5016 Efficacy in patient subgroups in RIBBON-1, a randomized, double-blind, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)

✍ V. Dieras; J. Glaspy; A. Brufsky; I. Bondarenko; O. Lipatov; E.A. Perez; S. Chan 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

RIBBON-2: A Randomized, Double-Blind, Pl

RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

✍ Datko, F.M.; Dickler, M.N. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 295 KB

Phase 2 study of eribulin mesylate as fi

Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

✍ McIntyre, Kristi; O’Shaughnessy, Joyce; Schwartzberg, Lee; Glück, Stefan; Berrak 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 405 KB

Motesanib, or open-label bevacizumab, in

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

✍ Miguel Martin; Henri Roche; Tamas Pinter; John Crown; M John Kennedy; Louise Pro 📂 Article 📅 2011 🏛 The Lancet 🌐 English ⚖ 230 KB

Erratum to: Phase 2 study of eribulin me

Erratum to: Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer

✍ McIntyre, Kristi; O’Shaughnessy, Joyce; Schwartzberg, Lee; Glück, Stefan; Berrak 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 127 KB